Clinical Trial Update: Single Agent ONC201 in Recurrent or Metastatic Endometrial Cancer [Phase 2]

View source ↗

Summary

A Phase 2 study of ONC201 as a single agent in recurrent or metastatic endometrial cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer

Drugs mentioned

• ONC201 (ONC201)

Snippet

Sponsor: Fox Chase Cancer Center | Conditions: Endometrial Cancer | Phase 2 | Status: TERMINATED